-
Pfizer inks generics deal with Chinese drug maker
NEW YORK — Pfizer has signed a deal worth more than $500 million with a Chinese drug maker to make generic drugs for China and other markets, the companies said.
Pfizer announced the joint venture with Zhejiang Hisun Pharmaceutical to develop, manufacture and commercialize generic drugs. Hisun will invest $295 million into the venture — called Hisun Pfizer Pharmaceutical Co. — and own a 51% stake, while Pfizer will invest $250 million and own 49%.
-
Breathing OTC life into asthma
Asthma has been becoming more relevant in the nonprescription aisles of late. Even as Armstrong Pharmaceuticals phases out what was an almost $100 million-and-growing brand in Primatene Mist — the Food and Drug Administration has removed any inhalers containing chlorofluorocarbons from the market — homeopathic supplier King Bio is currently presenting an alternative in its AsthmaCare product.